ClinicalTrials.gg
Enrolling by invitationNCT07825506Updated Sep 17, 2026

Fibromyalgia and Functional Impact: the Complementary Role of Neural Mobilization.

An interventional study of Conventional Treatment (CT) and Conventional Treatment plus Neural Mobilization (CTNM) in Fibromyalgia, Disabilities and Pain, sponsored by Pontificia Universidad Catolica de Chile. Enrolling by invitation at 1 site in Chile. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Pontificia Universidad Catolica de Chile · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This study aims to compare the change in overall impact and functional variables of fibromyalgia between a group receiving conventional treatment plus neural mobilization and a group receiving only conventional treatment over 12 weeks.

Read the detailed description

Fibromyalgia is a syndrome of chronic widespread pain with a high clinical and functional impact, characterized by persistent multisite pain, fatigue, sleep disturbances, cognitive symptoms, and reduced quality of life. In Chile, the estimated prevalence of fibromyalgia was reported to be 3.3% in the most recent national report on chronic pain, with a higher frequency in women. Despite advances in clinical recognition, diagnostic and therapeutic challenges persist, and a significant proportion of patients continue to experience pain and disability despite usual treatment. Current recommendations emphasize non-pharmacological and multidisciplinary management, especially education, therapeutic exercise, and self-management strategies. However, clinical response is variable, and there is still interest in identifying complementary interventions that improve the functional impact of the disease.Neural mobilization has shown benefits in neuromusculoskeletal conditions, and only one randomized clinical trial has been conducted in patients with fibromyalgia, reporting improvements in pain, fatigue, neurodynamic range, and functional status; however, the results were only evaluated after 8 weeks (short term), and the assessments were limited to questionnaires, pain intensity, and range in neurodynamic tests, without evaluating functionality with objective tests. On the other hand, it's very important to highlight that the clinical study carried out in 2014 looked at neural mobilization as an isolated therapy and was compared with a control group that only received education, without any active intervention or real therapeutic treatment. With all this background, we can say that the evidence for neurodynamics is still very limited, its long-term effects are unclear, and it's not well integrated into real physiotherapy programs in our setting.

02

Conditions studied

  • Fibromyalgia
  • Disabilities
  • Pain
  • Women

Keywords

  • disabilies
  • Fibromyalgia
  • Pain
  • Neural mobilization
  • Exercise
  • women
03

In context

Fibromyalgia

1,243 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

This study's planned enrollment of 20 is below the median of 60 across 937 interventional studies indexed under Fibromyalgia.

Browse Fibromyalgia studies →

Lead sponsor

Pontificia Universidad Catolica de Chile is the lead sponsor of 224 studies on the registry; 59 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 18 or older.
  • Medical diagnosis of fibromyalgia.
  • Ability to understand the study and sign .
  • Stable drug treatment for the 4 weeks prior.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy.
  • Active cancer or unstable systemic disease.
  • Severe decompensated psychiatric disorder.
  • Active substance dependence.
  • Inability to participate in therapeutic exercise or complete evaluations.
  • For the subsample with : use of anticoagulants, allergy to lidocaine, or active infection at the site.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
20 participants (estimated)

Study arms

  • Active comparator
    Conventional Treatment

    Education about pain and fibromyalgia, activity dosing, progressive therapeutic exercise (aerobic, strengthening, and mobility), and a home plan. Both groups will have the following materials and instruments: Instruments and materials: numeric pain scale/EVA, Revised Fibromyalgia Impact Questionnaire (FIQR), Pain Disability Questionnaire (PDQ), Pain Catastrophizing Scale, Chronic Pain Self-Efficacy Scale (or an equivalent validated instrument in Spanish), hand dynamometer, and pressure algometer. In a voluntary subsample, standardized QST will be applied, and a 3 mm punch skin biopsy will be offered, with additional specific consent, to obtain the sensory profile and quantify epidermal sensory fibers.

    Other: Conventional Treatment (CT)

  • Experimental
    Convencional Treatment plus Neural Mobilization

    Same conventional program plus standardized neural mobilization techniques, mainly of the 'slider' type, and progression according to clinical tolerance. Both groups will receive the same number and duration of sessions. Both groups will have the following materials and instruments: Instruments and materials: numeric pain scale/EVA, Revised Fibromyalgia Impact Questionnaire (FIQR), Pain Disability Questionnaire (PDQ), Pain Catastrophizing Scale, Chronic Pain Self-Efficacy Scale (or an equivalent validated instrument in Spanish), hand dynamometer, and pressure algometer. In a voluntary subsample, standardized QST will be applied, and a 3 mm punch skin biopsy will be offered, with additional specific consent, to obtain the sensory profile and quantify epidermal sensory fibers.

    Other: Conventional Treatment plus Neural Mobilization (CTNM)

Interventions

  • OtherConventional Treatment (CT)

    The intervention protocol was structured around a progressive "traffic light" model (red, yellow, and green) that takes into account the patients' pain levels and tolerance for movement. This approach is based on current recommendations for chronic pain management, which suggest adjusting the therapeutic load according to nervous system irritability to optimize clinical outcomes and prevent symptom flare-ups. Individualized load dosing has been shown to foster treatment adherence and improve functional outcomes, particularly in conditions characterized by central sensitization, such as fibromyalgia. In this context, the gradual progression of mechanical stimuli is a key rehabilitation principle, allowing for the progressive adaptation of tissues and the nervous system to increasing demands. The conventional group will receive a conventional physical therapy program based on aerobic, strength, and flexibility exercises, as well as pain education. Each session will last 60 minutes.

  • OtherConventional Treatment plus Neural Mobilization (CTNM)

    The intervention protocol is based on the same "traffic light" system used for the conventional group and the battery of components of protocol like: aerobic, strength, and flexibility exercise, and pain education. Regarding neural mobilization, sliding techniques ("sliders") have been described as generating lower levels of neural tension and being better tolerated during phases of high irritability, whereas tensioning techniques ("tensioners") increase mechanical load on the nervous system and are employed in later stages of treatment. Thus, starting with low-mechanical-load interventions focused on neural sliding and progressing to techniques incorporating longitudinal tension, rotational components, and global movements aligns with neurodynamic principles widely described in the literature. In addition to conventional treatment, this group will incorporate neural mobilization techniques organized according to the "traffic light" model.

06

What researchers measure

Primary outcomes

  1. FIQR - Revised Fibromyalgia Impact Questionnaire

    It's a medical and psychological tool specifically designed to assess and measure the impact fibromyalgia has on daily life, well-being, and patients' functional capacity. It's an update of the original FIQ questionnaire (created in 1991). It was modified to be easier to answer, simpler for doctors to score, and to include modern symptoms that were overlooked in the first version.This quiz has a score from 0 to 100.

    Time frame: Baseline and immediately after the 4-weeks intervention period.

Secondary outcomes

  1. NRS -- Numeric Rating Scale

    It is one of the most commonly used medical tools worldwide for quickly and easily measuring the intensity of a patient's pain. It consists of a numbered line from 0 to 10, where the patient chooses the number that best represents the strength or severity of their current pain. 0: Means a total absence of pain ("No pain"). 10: Represents the worst pain imaginable or the most intense pain the patient has ever felt.

    Time frame: Baseline and immediately after the session intervention for the 4-week intervention period.

  2. PCS -- Pain Catastrophizing Scale

    It's a psychological and medical questionnaire designed to measure the overly negative cognitive and emotional responses a person has to actual or anticipated pain. The total scale score ranges from 0 to 52 points. Low scores indicate a more resilient or adaptive attitude toward pain. A score of 30 or more is considered the clinical cutoff point for severe catastrophizing.

    Time frame: Baseline and immediately after the 4-week intervention period.

  3. PDQ -- Pain Disability Questionnaire

    It's a self-report tool designed to measure how and how intensely pain interferes with a person's daily life and functional ability. Unlike scales that only measure how much it hurts (like the NRS), the PDQ takes a biopsychosocial approach. This means it helps doctors understand how physical pain affects both body tasks and the patient's emotional and social well-being. By adding up the scores from all the questions, you get a total score that ranges from 0 to 150 points.

    Time frame: Baseline and immediately after the 4-week intervention period.

  4. PSEQ -- Pain Self-Efficacy Questionnaire

    It's a psychological and medical assessment tool designed to measure how confident a patient is in their own ability to carry out various daily activities despite experiencing chronic pain. Unlike other scales that measure fear or disability, the PSEQ evaluates the patient's resilience and sense of control over their life in the face of illness. By adding up the answers to the 10 questions, you get a total score that ranges from 0 to 60 points.

    Time frame: Baseline and immediately after the 4-week intervention period.

  5. Algometry

    Algometry (also known as dolorimetry) is a clinical and research method used to measure and quantify a patient's sensitivity and physical pain threshold objectively. Unlike questionnaires that rely entirely on the patient's verbal perception (like the NRS scale), algometry uses a mechanical or digital device called an algometer to apply a controlled physical stimulus (usually pressure) and record precise mathematical data. The most common type is pressure algometry, widely used in physiotherapy, rheumatology, and pain units.

    Time frame: Baseline and immediately after the 4-week intervention period.

  6. Dinamometry

    Dynamometry is a clinical and sports method used to measure muscle strength in an objective, precise, and quantifiable way. To carry it out, a mechanical or digital instrument called a dynamometer is used, which records the amount of physical force (usually measured in kilograms or Newtons) that a muscle group can generate during a maximum voluntary contraction. The most common and standardized type in medical practice is hand or palmar grip dynamometry (handgrip).

    Time frame: Baseline and immediately after the 4-week intervention period.

  7. IENFD -- density of intraepidermal nerve fibers.

    The density of intraepidermal nerve fibers (IENFD), assessed through a skin biopsy, is a diagnostic test considered the gold standard for identifying small fiber neuropathy (SFN). Unlike conventional electromyographies that only analyze the big nerves, this test lets doctors directly count how many microscopic nerve endings (A-delta and C fibers) are still alive in the outermost layer of the skin (the epidermis)

    Time frame: Baseline and immediately after the 4-week intervention period.

  8. QST -- Quantitative Sensory Testing.

    It's a non-invasive medical test that's used to accurately measure how a patient's somatosensory system (the nerves for touch, cold, heat, and pain) works. Unlike traditional neurological exams where the doctor pokes the skin with a needle and asks 'Do you feel this?', QST uses computer-calibrated physical stimuli to precisely determine the patient's exact perception and pain threshold.

    Time frame: Baseline and immediately after the 4-week intervention period.

07

Study locations

1 site
08

References and documents

Publications

  • Marshall A, Rapteas L, Burgess J, Riley D, Anson M, Matsumoto K, Bennett A, Kaye S, Marshall A, Dunham J, Fallon N, Zhao SS, Pritchard A, Goodson N, Malik RA, Goebel A, Frank B, Alam U. Small fibre pathology, small fibre symptoms and pain in fibromyalgia syndrome. Sci Rep. 2024 Feb 16;14(1):3947. doi: 10.1038/s41598-024-54365-6. PubMed 38365860 ↗
  • Basson A, Olivier B, Ellis R, Coppieters M, Stewart A, Mudzi W. The Effectiveness of Neural Mobilization for Neuromusculoskeletal Conditions: A Systematic Review and Meta-analysis. J Orthop Sports Phys Ther. 2017 Sep;47(9):593-615. doi: 10.2519/jospt.2017.7117. Epub 2017 Jul 13. PubMed 28704626 ↗
  • Torres JR, Martos IC, Sanchez IT, Rubio AO, Pelegrina AD, Valenza MC. Results of an Active Neurodynamic Mobilization Program in Patients With Fibromyalgia Syndrome: A Randomized Controlled Trial. Arch Phys Med Rehabil. 2015 Oct;96(10):1771-8. doi: 10.1016/j.apmr.2015.06.008. Epub 2015 Jul 2. PubMed 26143052 ↗
  • Li X, Pan H, Wang L, Zhou Q, Ma Y, Wang Q, Wang M, Xie Z, Li H, Chen L, Huang L, Chen Y, Wen C. Guidelines on Treating Fibromyalgia With Nonpharmacological Therapies in China. J Evid Based Med. 2025 Jun;18(2):e70044. doi: 10.1111/jebm.70044. PubMed 40500865 ↗
  • Iannuccelli C, Favretti M, Dolcini G, Di Carlo M, Pellegrino G, Bazzichi L, Atzeni F, Lucini D, Varassi G, Leoni MLG, Fornasari DMM, Conti F, Salaffi F, Sarzi-Puttini P, Di Franco M. Fibromyalgia: one year in review 2025. Clin Exp Rheumatol. 2025 Jun;43(6):957-969. doi: 10.55563/clinexprheumatol/buhd2z. Epub 2025 Jun 3. PubMed 40470564 ↗
  • Duran J, Tejos-Bravo M, Cid V, Ferreccio C, Calvo M. Chronic pain in Chile: first prevalence report of noncancer chronic pain, fibromyalgia, and neuropathic pain and its associated factors. Pain. 2023 Aug 1;164(8):1852-1859. doi: 10.1097/j.pain.0000000000002886. Epub 2023 Mar 9. PubMed 36893316 ↗
  • Delgado DA, Lambert BS, Boutris N, McCulloch PC, Robbins AB, Moreno MR, Harris JD. Validation of Digital Visual Analog Scale Pain Scoring With a Traditional Paper-based Visual Analog Scale in Adults. J Am Acad Orthop Surg Glob Res Rev. 2018 Mar 23;2(3):e088. doi: 10.5435/JAAOSGlobal-D-17-00088. eCollection 2018 Mar. PubMed 30211382 ↗
  • Hopewell S, Chan AW, Collins GS, Hrobjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials. BMJ. 2025 Apr 14;389:e081123. doi: 10.1136/bmj-2024-081123. PubMed 40228833 ↗
  • Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017 Jul 4;167(1):40-47. doi: 10.7326/M17-0046. Epub 2017 Jun 20. PubMed 28630973 ↗

Individual participant data

Plan to share: Undecided — The small sample size of the study may limit the ability to fully ensure participant confidentiality if individual-level data were to be shared.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07825506
Responsible party
Sponsor
First posted
Sep 17, 2026
Start date
Aug 25, 2026
Primary completion
Oct 30, 2026 (estimated)
Completion
Nov 25, 2026 (estimated)
Last update
Sep 17, 2026

Study contacts

Gustavo Torres
principal investigator · Pontificia Universidad Catolica de Chile

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion